Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$48.11 USD
+0.49 (1.03%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.10 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.11 USD
+0.49 (1.03%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.10 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
by Zacks Equity Research
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
by Zacks Equity Research
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
by Zacks Equity Research
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Medicare Releases Negotiated Prices on 10 Expensive Drugs
by Sundeep Ganoria
Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.
All You Need to Know About Bristol Myers (BMY) Rating Upgrade to Buy
by Zacks Equity Research
Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BMY vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. VRTX: Which Stock Is the Better Value Option?
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
by Zacks Equity Research
A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?
by Ekta Bagri
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
by Zacks Equity Research
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Bristol Myers Squibb (BMY) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
by Ekta Bagri
Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.
BMY vs. VRTX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. VRTX: Which Stock Is the Better Value Option?
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Company News for Jul 29, 2024
by Zacks Equity Research
Companies in The News Are: NSC, CHTR, CL, BMY
PCE/Core PCE Inflation In Line With Estimates in June
by Zacks Equity Research
PCE/Core PCE Inflation In Line With Estimates in June.
Pre-Markets Swell, PCE Behaves, Several Q2 Beats
by Mark Vickery
Pre-market futures are jumping this morning, though this may have to do with favorable market conditions after the sell-off mid-week.
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 26.22% and 5.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DECK, SKX Higher After Earnings; PCE On Tap Friday
by Mark Vickery
The maker of Hoka footwear, UGG boots and more, posted a giant beat on its fiscal Q1 bottom line.